博碩士論文行動網

論文名稱(外文):, The role of histone methyltransferase EZH2 in drug resistant ovarian cancer cells. 指導教授: 李龍緣. 指導教授(外文):, Long-Yuan Li. 資料載入處理中... 跳到主要內容 臺灣博碩士論文加值系統 ::: 網站導覽| 首頁| 關於本站| 聯絡我們| 國圖首頁| 常見問題| 操作說明 English |FB專頁 |Mobile 免費會員 登入| 註冊 功能切換導覽列 (167.99.71.17)您好！臺灣時間：2021/12/2717:27 字體大小：       ::: 詳目顯示 recordfocus 第1筆/ 共1筆  /1頁 論文基本資料 摘要 外文摘要 目次 參考文獻 QRCode 本論文永久網址: 複製永久網址Twitter研究生:王奕筑研究生(外文):I-ChuWang論文名稱:探討組蛋白甲基轉移酶EZH2在抗藥性卵巢癌細胞中的角色論文名稱(外文):TheroleofhistonemethyltransferaseEZH2indrugresistantovariancancercells指導教授:李龍緣指導教授(外文):Long-YuanLi口試委員:呂仁、蘇鴻麟口試委員(外文):RenLu、Hong-LinSu口試日期:2018-07-31學位類別:碩士校院名稱:國立中興大學系所名稱:生命科學系所學門:生命科學學門學類:生物學類論文種類:學術論文論文出版年:2018畢業學年度:106語文別:中文論文頁數:43中文關鍵詞:組蛋白甲基轉移酶、抗藥性、卵巢癌外文關鍵詞:EZH2、drugresistant、ovariancancer相關次數: 被引用:0點閱:144評分:下載:0書目收藏:0 卵巢癌為女性十大癌症死因其中之一。

卵巢癌並沒有明顯的症狀，所以大部份的婦女當被診斷是卵巢癌時，通常都已經擴散成為較晚期的癌症。

紫杉醇是用於治療晚期卵巢癌的一線化學治療用藥，在診斷時，大約70％的卵巢癌對化療藥物相當敏感，但是耐藥性的快速發展和癌細胞的轉移導致後期治療失敗和疾病惡化。

Enhancerofzestehomolog2(EZH2)為一種組蛋白甲基轉移酶，其為PolycombRepressiveComplex2(PRC2)的催化亞基，在其C端的SET結構域對組蛋白H3上的Lys27接上三個甲基(H3K27me3)，使目標基因靜默並在癌症中誘導上皮-間質轉化(EMT)以及抗藥性，參與多種生物功能例如細胞增殖、細胞週期和細胞分化等。

為了進一步探討EZH2在抗藥性卵巢癌細胞中的表現與相關機制，我們利用westernblotting來檢測卵巢癌細胞中EZH2的表現，以transwell來測證明EZH2能促進卵巢癌細胞遷移與侵襲能力，並利用shRNA抑制EZH2在卵巢癌細胞中的表現，加以驗證EZH2對卵巢癌細胞的影響，證明抑制EZH2的表現能使卵巢癌細胞遷移與侵襲能力降低。

利用westernblotting觀察EZH2對卵巢癌細胞中EMT的發展，發現EZH2會抑制上皮標記物和促進間質標記物的表現使卵巢癌細胞發生EMT。

最後以細胞活性測定評估EZH2對細胞存活以及對紫杉醇耐藥性的影響，抑制EZH2後加入紫杉醇確實能降低癌細胞的活性，使卵巢癌細胞耐藥性降低。

Ovariancancerisoneofthetoptencausesofcancerdeathamongwomen.Ovariancancerhasnotobvioussymptoms,whichcanresultinlatedetection.Paclitaxelisusedasfirstlinetherapyforadvancedovariancancer.Roughly70%ofovariancancersaresensitivetochemotherapyatdiagnosis,butrapidlydevelopdrugresistanceandmetastasisleadingtotreatmentfailureanddiseaseprogression.Enhancerofzestehomolog2(EZH2)isahistonemethyltransferase.EZH2hasbeenidentifiedasacatalyticsubunitofPolycombRepressiveComplex2(PRC2)fortri-methylationofhistoneH3atLys27(H3K27me3)bySETdomaininitsC-terminus.Itsilencestargetedgenesandmediatestheactivationofepithelialtomesenchymaltransition(EMT)inmanycancers.EZH2isinvolvedinvariousbiologicalfunctions,suchascellproliferation,cellcycleandcelldifferentiation.TofurtherinvestigatetheexpressionandmechanismofEZH2inovariancancercells.WeusedwesternblottingtodetecttheexpressionofEZH2inovariancancercells.TranswellassaysprovethatEZH2canpromotethemigrationandinvasionofovariancancercells.InhibitionofEZH2expressionusingshRNAcanreducethemigrationandinvasionofovariancancercells.ToobservetheeffectsofEZH2onEMTofovariancancercellsbywesternblotting,theresultsshowthatEZH2inhibitsepithelialmarkersandpromotestheexpressionofmesenchymalmarkerstocauseEMTinovariancancercells.Moreover,theeffectsofEZH2oncellsurvivalandpaclitaxelresistancewereevaluatedbycellviabilityassay.InhibitionofEZH2canreducethedrugresistanceandcellviabilityofovariancancercells 中文摘要.........iAbstract.........ii目次.............iii縮寫.............iv第一章、前言...........1(一)、人類卵巢癌介紹..........1(二)、Enhancerofzestehomolog2(EZH2)...........1(三)、上皮–間質轉化..............3第二章、研究目的與動機............5第三章、材料與方法.............6(一)、實驗材料.................6(二)、實驗方法....................81、蛋白質膠體電泳分析(SDS-PAGE).....................82、西方轉漬法(WesternBlot).................83、細胞遷移(MigrationAssay)................94、細胞侵入(InvasionAssay).................95、細胞存活率分析(MTTAssay).................96、細胞培養.........................101A9、1A9PTX10和1A9PTX22...............10SKOV3和SKOV3ip1......................107、細胞轉染(Celltransfection)..............118、統計分析.................11第四章、結果.............12第五章、討論...............16第六章、結論...................18參考文獻................19圖..................23 1.Torre,LindseyA,BrittonTrabert,CarolEDeSantis,KimberlyDMiller,GoliSamimi,CarolynDRunowicz,MiaMGaudet,AhmedinJemal,andRebeccaLSiegel.2018.''Ovariancancerstatistics,2018'',CA:acancerjournalforclinicians.2.Huang,Yan,LenardMLichtenberger,MorganTaylor,JustinNBottsford-Miller,MonikaHaemmerle,MichaelJWagner,YasminLyons,SunilaPradeep,WeiHu,andRebeccaAPrevis.2016.''Anti-tumorandanti-angiogeniceffectsofaspirin-PCinovariancancer'',Molecularcancertherapeutics:molcanther.0074.2016.3.Sung,Pi-Lin,Kuo-ChangWen,Yi-JenChen,Ta-ChungChao,Yi-FangTsai,Ling-MingTseng,Jian-TaiTimothyQiu,Kuan-ChongChao,Hua-HsiWu,andChi-MuChuang.2017.''ThefrequencyofcancerpredispositiongenemutationsinhereditarybreastandovariancancerpatientsinTaiwan:FromBRCA1/2tomulti-genepanels'',PloSone,12:e0185615.4.Reid,BrettM,JenniferBPermuth,andThomasASellers.2017.''Epidemiologyofovariancancer:areview'',Cancerbiology&medicine,14:9.5.Cortez,AlexanderJ,PatrycjaTudrej,KatarzynaAKujawa,andKatarzynaMLisowska.2018.''Advancesinovariancancertherapy'',Cancerchemotherapyandpharmacology:1-22.6.Siegel,Rebecca,JieminMa,ZhaohuiZou,andAhmedinJemal.2014.''Cancerstatistics,2014'',CA:acancerjournalforclinicians,64:9-29.7.Meacham,CorbinE,andSeanJMorrison.2013.''Tumourheterogeneityandcancercellplasticity'',Nature,501:328.8.Tomao,Federica,AnselmoPapa,MartinaStrudel,LuigiRossi,GiuseppeLoRusso,PierluigiBenedettiPanici,FrancescaRomanaCiabatta,andSilverioTomao.2014.''Investigatingmolecularprofilesofovariancancer:anupdateoncancerstemcells'',JournalofCancer,5:301.9.Abubaker,Khalid,ArdianLatifi,RodLuwor,SimonNazaretian,HongjianZhu,MichaelAQuinn,ErikWThompson,JockKFindlay,andNuzhatAhmed.2013.''Short-termsingletreatmentofchemotherapyresultsintheenrichmentofovariancancerstemcell-likecellsleadingtoanincreasedtumorburden'',Molecularcancer,12:24.10.Margueron,Raphaël,andDannyReinberg.2011.''ThePolycombcomplexPRC2anditsmarkinlife'',Nature,469:343.11.Pasini,Diego,andLucianoDiCroce.2016.''EmergingrolesforPolycombproteinsincancer'',Currentopinioningenetics&development,36:50-58.12.Carvalho,Joana,NicoleCvanGrieken,PatriciaMPereira,SóniaSousa,MarianneTijssen,TinekeEBuffart,BegoñaDiosdado,HeikeGrabsch,ManuelASSantos,andGerritMeijer.2012.''LackofmicroRNA‐101causesE‐cadherinfunctionalderegulationthroughEZH2up‐regulationinintestinalgastriccancer'',TheJournalofpathology,228:31-44.13.Feng,Hai,ZhuoYu,YuanTian,Ying-YingLee,MaySLi,MinnieYYGo,Yue-SunCheung,PaulBSLai,AndrewMLChan,andKa-FaiTo.2015.''ACCRK-EZH2epigeneticcircuitrydriveshepatocarcinogenesisandassociateswithtumorrecurrenceandpoorsurvivalofpatients'',Journalofhepatology,62:1100-11.14.Xie,Huafeng,CongPeng,JialiangHuang,BinELi,WoojinKim,ElenoeCSmith,YukoFujiwara,JunQi,GiuliaCheloni,andParthaPDas.2016.''ChronicmyelogenousleukemiainitiatingcellsrequirePolycombgroupproteinEZH2'',Cancerdiscovery:CD-15-1439.15.Ma,De-Ning,Zong-TaoChai,Xiao-DongZhu,NingZhang,Di-HuaZhan,Bo-GenYe,Cheng-HaoWang,Cheng-DongQin,Yi-MingZhao,andWei-PingZhu.2016.''MicroRNA-26asuppressesepithelial-mesenchymaltransitioninhumanhepatocellularcarcinomabyrepressingenhancerofzestehomolog2'',Journalofhematology&oncology,9:1.16.Cao,Qi,JindanYu,SaravanaMDhanasekaran,JungHKim,Ram-ShankarMani,ScottATomlins,RohitMehra,BharathiLaxman,XuhongCao,andCGKleer.2008.''RepressionofE-cadherinbythepolycombgroupproteinEZH2incancer'',Oncogene,27:7274.17.Yi,Xiaoqing,JianfengGuo,JingGuo,SiSun,PingYang,JunjieWang,YuanLi,LishaXie,JingCai,andZehuaWang.2017.''EZH2-mediatedepigeneticsilencingofTIMP2promotesovariancancermigrationandinvasion'',ScientificReports,7:3568.18.Mahara,Sylvia,PuayLengLee,MinFeng,VinayTergaonkar,WeeJooChng,andQiangYu.2016.''HIFI-αactivationunderliesafunctionalswitchintheparadoxicalroleofEzh2/PRC2inbreastcancer'',ProceedingsoftheNationalAcademyofSciences,113:E3735-E44.19.Wang,Jianmei,XiaohuiZhu,JinlongHu,GuoyangHe,XiaomeiLi,PingxiangWu,XiaoliRen,FeifeiWang,WentingLiao,andLiLiang.2015.''ThepositivefeedbackbetweenSnailandDAB2IPregulatesEMT,invasionandmetastasisincolorectalcancer'',Oncotarget,6:27427.20.Tiwari,Neha,VijayKTiwari,LorenzWaldmeier,PiotrJBalwierz,PhilArnold,MikhailPachkov,NathalieMeyer-Schaller,DirkSchübeler,ErikvanNimwegen,andGerhardChristofori.2013.''Sox4isamasterregulatorofepithelial-mesenchymaltransitionbycontrollingEzh2expressionandepigeneticreprogramming'',Cancercell,23:768-83.21.Gardner,EricE,BenjaminHLok,ValentinaESchneeberger,PatriceDesmeules,LindeAMiles,PaigeKArnold,AndyNi,InnaKhodos,ElisadeStanchina,andThuyenNguyen.2017.''ChemosensitiverelapseinsmallcelllungcancerproceedsthroughanEZH2-SLFN11axis'',CancerCell,31:286-99.22.Fan,Tian-Yu,HaiWang,PengXiang,Ya-WeiLiu,He-ZhenLi,Bing-XiLei,MengYu,andSong-TaoQi.2014.''InhibitionofEZH2reverseschemotherapeuticdrugTMZchemosensitivityinglioblastoma'',Internationaljournalofclinicalandexperimentalpathology,7:6662.23.Rao,Zhi-Yue,Mu-YanCai,Guo-FenYang,Li-RuHe,Shi-JuanMai,Wen-FengHua,Yi-JiLiao,Hai-XiaDeng,Yang-ChaoChen,andXin-YuanGuan.2010.''EZH2supportsovariancarcinomacellinvasionand/ormetastasisviaregulationofTGF-β1andisapredictorofoutcomeinovariancarcinomapatients'',Carcinogenesis,31:1576-83.24.Scanlon,CS,EAVanTubergen,RCInglehart,andNJD’Silva.2013.''Biomarkersofepithelial-mesenchymaltransitioninsquamouscellcarcinoma'',Journalofdentalresearch,92:114-21.25.Ceppi,P,andMEPeter.2014.''MicroRNAsregulatebothepithelial-to-mesenchymaltransitionandcancerstemcells'',Oncogene,33:269.26.Zheng,H,andYKang.2014.''MultilayercontroloftheEMTmasterregulators'',Oncogene,33:1755.27.Yang,Cong-Chong,Li-FangZhu,Xiao-HuiXu,Tian-YunNing,Jin-HaiYe,andLai-KuiLiu.2013.''MembraneType1MatrixMetalloproteinaseinducesanepithelialtomesenchymaltransitionandcancerstemcell-likepropertiesinSCC9cells'',BMCcancer,13:171.28.Perdigao-Henriques,R,FPetrocca,GAltschuler,MPThomas,MTNLe,SMTan,WHide,andJLieberman.2016.''miR-200promotesthemesenchymaltoepithelialtransitionbysuppressingmultiplemembersoftheZeb2andSnail1transcriptionalrepressorcomplexes'',Oncogene,35:158.29.Liu,Xiqiang,ChengWang,ZujianChen,YiJin,YunWang,AntoniaKolokythas,YangDai,andXiaofengZhou.2011.''MicroRNA-138suppressesepithelial–mesenchymaltransitioninsquamouscellcarcinomacelllines'',BiochemicalJournal,440:23-31.30.Zaravinos,A.(2015).TheregulatoryroleofmicroRNAsinEMTandcancer.Journalofoncology,2015.31.Giannakakou,Paraskevi,DanLSackett,Yoon-KooKang,ZhirongZhan,JeroenTMButers,TitoFojo,andMarianneSPoruchynsky.1997.''Paclitaxel-resistanthumanovariancancercellshavemutantβ-tubulinsthatexhibitimpairedpaclitaxel-drivenpolymerization'',JournalofBiologicalChemistry,272:17118-25.32.Lee,Yoo-Young,Hye-KyungJeon,JiEunHong,YoungJaeCho,JiYoonRyu,Jung-JooChoi,SangHoonLee,GunYoon,WooYoungKim,andIn-GuDo.2015.''Protonpumpinhibitorsenhancetheeffectsofcytotoxicagentsinchemoresistantepithelialovariancarcinoma'',Oncotarget,6:35040.33.Zhao,Zhangxiang,WenbinZhou,YueHan,FuduanPeng,RuipingWang,RuihanYu,ChengyuWang,HaihaiLiang,ZhengGuo,andYunyanGu.2017.''EMT-Regulome:adatabaseforEMT-relatedregulatoryinteractions,motifsandnetwork'',Celldeath&disease,8:e2872.34.Lili,LoukiaN,LilyaVMatyunina,LDeEtteWalker,StephenLWells,BenedictBBenigno,andJohnFMcDonald.2013.''Molecularprofilingsupportstheroleofepithelial-to-mesenchymaltransition(EMT)inovariancancermetastasis'',Journalofovarianresearch,6:49.35.Kim,KimberlyH,andCharlesWMRoberts.2016.''TargetingEZH2incancer'',Naturemedicine,22:128. 推文 網路書籤 推薦 評分 引用網址 轉寄                                                                                                                                                                                                                    top 相關論文 相關期刊 熱門點閱論文 1. 篩選新型治療惡性卵巢癌的藥物 2. TGF-beta/EZH2標的基因表現量作為卵巢癌病人之存活預測指標之探討 3. 組蛋白甲基轉移酶G9a在卵巢癌腹膜腔轉移及浸襲之角色評估   無相關期刊   1. 新型小分子化合物對於間質幹細胞年齡依賴性分化之影響 2. 探討介白素19在急性骨髓性白血病中之角色 3. 新穎化合物對人類間質幹細胞分化成骨頭及脂肪細胞的影響 4. 探討組蛋白甲基轉移酶對於乳癌細胞上皮間質轉化之影響 5. 探討EZH2在調控乳癌細胞移動及侵襲中所扮演的角色 6. 篩選抑制經由發炎介導mTOR路徑腫瘤發生的新穎抑制劑 7. 探討微核糖核酸與間質幹細胞年齡依賴性分化之相關性 8. 探討組蛋白甲基轉移酶對於抗藥性卵巢癌細胞增殖與存活之影響 9. 探討TGFβ引起細胞核形異常的機轉 10. 探討特異性基因治療對於表達HBx蛋白的肝癌細胞抑制效果 11. 我是同志,但我也是基督徒-談同志的教會經驗 12. 以鼓膜隔艙壓力試驗法探討次微米鈦鎳合金薄膜之機械行為 13. 寄生在太田樹蛙之Endotrombiculasp.生物特性 14. 溫室內噴霧降溫設計基準之建置與飽差利用之控制器研發 15. 人類第四型胜肽精胺酸脫亞胺酶瓜胺酸化人類抗酶與p53蛋白之功能性研究     簡易查詢 | 進階查詢 | 熱門排行 | 我的研究室